Behzad Aghazadeh

Avoro Capital’s Behzad Aghazadeh is among the most prominent investors in biotech, delivering consistent returns at his $6 billion hedge fund. Speaking with STAT’s Adam Feuerstein late last year about what’s ahead for biotech in 2024, Aghazadeh noted that in the wake of the industry’s recent tumult, Avoro’s approach to evaluating whether companies are a good investment has evolved accordingly. “We spend a lot more time evaluating management teams,” he said. “We need to make sure they’ve worked together and banded together and succeeded together.”